RLMD — Relmada Therapeutics, Inc. stock price, charts and financials

Latest market price

4.59

-0.34-6.98%

Overview Short InterestFilings

RLMDQT91Relmada Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

4.59-6.98%

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.02%$15.53 MESO+4.33%$16.63 ZBIO-1.09%$32.08 GHRS-1.37%$29.86 TSHA-1.75%$6.45 STOK-1.62%$32.18 ABCL+35.57%$9.39 VRDN-2.37%$23.03

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	6.18%	Shs Outstand	104.89M	Perf Week	-6.97%

Market Cap	518.16M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-	Shs Float	90.42M	Perf Month	-24.12%

Enterprise Value	506.82M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	14.37%	Perf Quarter	-33.51%

Income	-57.77M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	8.08	Perf Half Y	37.22%

Sales	0.00	P/B	2.69	EPS next Y	-16.73%	ROA	-28.27%	Short Interest	12.99M	Perf YTD	2.28%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-47.52%	52W High	7.44 -38.25%	Perf Year	724.71%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-30.78%	52W Low	0.51 798.18%	Perf 3Y	668.87%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.63% 6.78%	Perf 5Y	-5.00%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	58.87%	Oper. Margin	0.00%	ATR (14)	0.38	Perf 10Y	212.66%

Dividend Ex-Date	-	Quick Ratio	29.52	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	33.65	Recom	2.50

Dividend Gr. 3/5Y	-	Current Ratio	29.52	EPS Q/Q	62.07%	SMA20	-8.52%	Beta	0.31	Target Price	11.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-18.77%	Rel Volume	1.24	Prev Close	4.94

Employees	17	LT Debt/Eq	-0.50	Earnings	Nov 12	SMA200	-6.72%	Avg Volume	1.72M	Price	4.59

IPO Date	Jun 20, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.81% -	Net Debt/EBITDA	0.18	Volume	2,125,012	Change	-6.98%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-18-26	Initiated	H.C	Buy	$12
Mar-13-26	Reiterated	Mizuho Securities	Outperform	$10
Jan-23-26	Upgrade	Leerink Partners	Market Perform → Outperform	$8.00
Dec-22-25	Initiated	Jefferies	Buy	$8.00 → $9.00
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Dec-04-24	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-05-24	Downgrade	Goldman Sachs	Neutral → Sell	$2.00
Oct-14-22	Downgrade	Goldman Sachs	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral

Latest News

Aug-07-26

Aug-07-2607:04AM

Relmada Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

04:54AM

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcriptseekingalpha.com

Aug-04-26

Aug-04-2602:15AM

Critical Review: Relmada Therapeutics (NASDAQ:RLMD) versus Novo Nordisk A/S (NYSE:NVO)defenseworld.net

Jul-29-26

Jul-29-2603:45AM

ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMDdefenseworld.net

Jul-28-26

Jul-28-2608:30AM

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officerglobenewswire.com

Jul-19-26

Jul-19-2604:03AM

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short Interestdefenseworld.net

Jul-16-26

Jul-16-2607:05AM

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026globenewswire.com

Jun-29-26

Jun-29-2607:08AM

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 IndexBenzinga

07:00AM

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexesglobenewswire.com

Jun-19-26

Jun-19-2610:47AM

Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock TodaySeekingAlpha

Jun-18-26

Jun-18-2601:38PM

Relmada's Cancer Drug Candidate Sparks Fresh Bullish CallBenzinga

07:45AM

This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga

06:06AM

HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12Benzinga

Company

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 6/30/2019	FY 2017 6/30/2018
Total Revenue	0	0	0	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	0	38	49	—	—	—	—	—	—
Research and Development	1	46	55	—	—	—	—	—	—
Other Operating Expense	58	0	0	—	—	—	—	—	—
Operating Income	-59	-84	-104	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	2	4	5	—	—	—	—	—	—
Net Income Before Taxes	-57	-80	-99	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-57	-80	-99	—	—	—	—	—	—
Net Income From Continuing Operations	-57	-80	-99	—	—	—	—	—	—
Net Income	-57	-80	-99	—	—	—	—	—	—
EPS (Recurring)	-1.45	-2.65	-3.28	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.45	-2.65	-3.28	—	—	—	—	—	—
EPS (Diluted)	-1.45	-2.65	-3.28	—	—	—	—	—	—
EBITDA	-57	-80	5	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	39	30	30	—	—	—	—	—	—
Market Capitalization	188	16	31	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TRAVERSA SERGIO	Chief Executive Officer	Dec 15 '25	Buy	4.12	27,500	113,300	1,300,000	Dec 16
Shenouda Maged	Chief Financial Officer	Dec 15 '25	Buy	4.12	11,665	48,060	800,000	Dec 16
Shenouda Maged	Chief Financial Officer	Nov 05 '25	Buy	2.20	500,000	1,100,000	788,335	Nov 06
Ence Chuck	CAO and COO	Nov 05 '25	Buy	2.20	136,000	299,200	403,931	Nov 06
TRAVERSA SERGIO	Chief Executive Officer	Nov 05 '25	Buy	2.20	272,500	599,500	1,272,500	Nov 06
Kelly Paul Edward	Chief Operating Officer	Nov 05 '25	Buy	2.20	90,000	198,000	502,295	Nov 06
TRAVERSA SERGIO	Chief Executive Officer	Aug 28 '25	Buy	0.74	55,976	41,422	1,000,000	Aug 28
TRAVERSA SERGIO	Chief Executive Officer	Aug 27 '25	Buy	0.67	129,455	86,735	944,024	Aug 28
TRAVERSA SERGIO	Chief Executive Officer	Aug 26 '25	Buy	0.62	80,545	49,938	814,569	Aug 28
TRAVERSA SERGIO	Chief Executive Officer	May 20 '25	Buy	0.56	147,686	82,246	734,024	May 20
Shenouda Maged	Chief Financial Officer	May 20 '25	Buy	0.52	60,000	31,422	288,335	May 20
Shenouda Maged	Chief Financial Officer	May 19 '25	Buy	0.49	90,000	43,686	228,335	May 20
TRAVERSA SERGIO	Chief Executive Officer	May 19 '25	Buy	0.50	30,000	14,994	586,338	May 20
TRAVERSA SERGIO	Chief Executive Officer	May 16 '25	Buy	0.45	172,314	77,472	556,338	May 20
Shenouda Maged	Chief Financial Officer	May 16 '25	Buy	0.44	50,000	22,100	138,335	May 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.